These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 18587731

  • 1. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
    Locatelli F, Villa G, Messa P, Filippini A, Cannella G, De Ferrari G, Naso A, Rossi E, Formica M, Lombardi L, Rotolo U, Conte F.
    J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
    [Abstract] [Full Text] [Related]

  • 2. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 3. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [Abstract] [Full Text] [Related]

  • 4. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 5. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U.
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M, Vetter A, Thyroff-Friesinger U, INJ-Study Group.
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Once-every-2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients.
    Mircescu G, Gârneată L, Ciocâlteu A, Golea O, Gherman-Căprioară M, Capsa D, Mota E, Gusbeth-Tatomir P, Ghenu A, Bălută S, Constantinovici N, Covic AC.
    Am J Kidney Dis; 2006 Sep; 48(3):445-55. PubMed ID: 16931218
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ, Kent AB, Becker GJ, McMahon LP.
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [Abstract] [Full Text] [Related]

  • 16. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 17. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
    Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U, RUBRA Study Investigators.
    Am J Nephrol; 2008 Jul; 28(2):280-9. PubMed ID: 18004064
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia.
    Grzeszczak W, Sulowicz W, Rutkowski B, de Vecchi AF, Scanziani R, Durand PY, Bajo A, Vargemezis V, European Collaborative Group.
    Nephrol Dial Transplant; 2005 May; 20(5):936-44. PubMed ID: 15769814
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [Abstract] [Full Text] [Related]

  • 20. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
    Milutinović S, Plavljanić E, Trkulja V.
    Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.